Opdivo – Talk Bio

Ono’s BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial

5 days ago talkbio0Tagged Advanced phase, Bristol Myers Squibb, EP4 antagonist, EP4 Antagonist ONO-4578, Episodic, HER2-negative, Malignant neoplasm of stomach, nivolumab, Opdivo, Pharmacotherapy, Phase 2, Progression-Free Survival

ONO-4578; EP4 antagonist; gastric cancer; Opdivo; nivolumab; Bristol-Myers Squibb; phase 2; progression-free survival; chemotherapy; HER2-negative; advanced; recurrent

Recent Law Expands Orphan Drug Protections, Shielding Blockbusters from Medicare Price Negotiations

2 weeks ago talkbio0Tagged Big Beautiful Bill, Congress (U.S. Legislature), Drug Industry, drug price, Inflation Reduction Act, Keytruda, Medicare, negotiation, OBBBA, Opdivo, orphan drug exclusion

orphan drug exclusion; Medicare negotiation; One Big Beautiful Bill; Keytruda; Opdivo; Inflation Reduction Act; OBBBA; drug pricing; Congress; pharmaceutical industry

Survival Benefit of Amgen’s Bemarituzumab in Gastric Cancer Attenuates at Final Analysis

1 month ago talkbio0Tagged amgen, Attenuated by (contextual qualifier), bemarituzumab, Benefit, final analysis, FORTITUDE-101, FORTITUDE-102, Malignant neoplasm of stomach, nivolumab, Opdivo, Overall Survival, Zai Lab

Amgen; bemarituzumab; gastric cancer; Phase 3 trial; overall survival; attenuated benefit; final analysis; FORTITUDE-101; FORTITUDE-102; Zai Lab; Opdivo; nivolumab

Bristol Myers CMO Addresses LAG-3 Concerns After Opdualag’s Adjuvant Melanoma Setback at ASCO 2025

4 months ago talkbio0Tagged Adjuvant Melanoma, ASCO, Clinical Trials, lymphocyte-activation gene 3 protein, human, Malignant neoplasm of lung, Myers, Opdivo, Opdualag, relatlimab, squibb

Opdualag; Bristol Myers Squibb; LAG-3; lung cancer; adjuvant melanoma; ASCO 2025; Opdivo; relatlimab; clinical trial

Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025

9 months ago talkbio0Tagged 2025, Braftovi, Cancer Therapeutic Procedure, Colorectal Carcinoma, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, Myers, Opdivo, Pfizer, squibb, Yervoy

Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.

FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer

1 year ago talkbio0Tagged Adjuvant Therapy, Approved, CheckMate-77 T trial, Neoadjuvant Therapy, nivolumab, Non-Small Cell Lung Carcinoma, Opdivo, perioperative, United States Food and Drug Administration

Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy